AIDS Vaccine Conference Ends with Eye to Future

Joe DeCapua Bangkok, Thailand, September 15, 2011 Source: http://www.voanews.com/english/news/africa/decapua-aids-vaccine-closing-15sept11129884818.html

- The AIDS Vaccine 2011 conference ended Thursday in Bangkok, Thailand. - About 850 scientists, researchers and others met for 4 days to discuss progress on finding a vaccine to prevent HIV infection. Mitchell Warren: head of the AIDS Vaccine Advocacy Coalition (AVAC) AVAC: non-profit, ethical development, delivery of AIDS vaccines Thailand: the first and largest AIDS vaccine trial in the world That vaccine candidate: RV-144. About 16,000 participants in 2009; protection rate about 31% Not definite answers, but rather new signals A follow-up trial to RV-144 in 2014. 2,200 participants in about 20 U.S. cities. among men who have sex with men and transgender women. Sponsor: HIV Vaccine Trials Network. Vaccine trials: more complicated, more interesting in the next couple of years Near and midterm strategies: scaling up treatment and care, condoms, male circumcisio… => help control epidemic Long term strategy: AIDS vaccine => an end to the epidemic AIDS Vaccine 2012: next September in Boston, Massachusetts.

The AIDS Vaccine 2011 conference ended Thursday in Bangkok, Thailand. While a vaccine to help end the pandemic remains elusive, scientific advances are being made. About 850 scientists, researchers and others met for four days to discuss progress on finding a vaccine to prevent HIV infection. It’s the only conference to focus exclusively on that. Exciting time Mitchell Warren, head of the AIDS Vaccine Advocacy Coalition, or AVAC, gives the meeting fairly high marks. “I’d say on a scale from one to ten, we are in a scientific zone in the upper sevens and eights,” he said. AVAC is a non-profit organization with a stated goal speeding up the “ethical development and delivery of AIDS vaccines” as part of a “comprehensive response to the pandemic.”

200 participants in about 20 U. Now what? Warren said. he says. The results of the trial involving about 16. These are complexities and challenges that we’ve longed for. “The near term and midterm strategies are the ones that are going to help us begin to control the epidemic.” What they found were not definite answers. “While this is one of the most exciting times in our field. The near and midterm strategies.not nearly good enough to go to market. They showed a protection rate of about 31 percent . HVTN 505 is the world’s largest ongoing HIV vaccine study and uses a combination of two experimental vaccines.and the first trial to demonstrate that a vaccine was possible – it’s pretty exciting timing.” said Warren. an unprecedented international collaboration has been underway to try to understand why we got the modest effect in that trial that we did. . it is also the most complex time in our field. Three-part strategy He added that in these difficult economic times. should include scaling up treatment and care. Meanwhile. Massachusetts.S. It’s sponsored by the HIV Vaccine Trials Network. a comprehensive strategic plan is needed for HIV/AIDS.” he said. AIDS Vaccine 2012 will be held next September in Boston.” he said. there is a vaccine trial that’s currently recruiting 2. but rather new signals of what direction to take next. “Over the last two years. It will focus on preventing infection among men who have sex with men and transgender women. A follow-up trial to RV-144 will be held in 2014. male circumcision.“We are in a terrific moment in the field and I must say it is terrifically exciting to be able to do this meeting here in Bangkok. The long term strategy will get us an end to the epidemic. But these are the first signals we’ve ever had. but more interesting in the next couple of years. The long term strategy is an AIDS vaccine. That vaccine candidate is known as RV-144. I think it’s safe to say that vaccine trials are going to get more complicated.” he said. but good enough to show it can be done. but to be in the country where the largest AIDS vaccine trial in the world took place . It’s not just good science. “It is what we call hypothesis generating and there is going to need to be some additional studies to confirm that. microbicides and the use of antiretroviral drugs as a preventive measure.000 participants were announced in 2009. cities. It will reflect new the data and direction developed since 2009. condoms.